Investor Presentaiton
Because precision and speed
impact patients
ascopubs.org/journal/po
JCO®
Precision Oncology
An American Society of Clinical Oncology Journal
CGP results in
4x better patient
outcomes
Every month delayed
in cancer treatment
can raise risk of death
by around 10%¹
]
ASCO
KNOWLEDGE CONQUERS CANCER
+
Association Between Availability of
Molecular Genotyping Results and
Overall Survival in Patients With
Advanced Nonsquamous
Non-Small-Cell Lung Cancer
Charu Aggarwal, MD, MPH; Melina E. Marmarelis, MD, MSCE;
Wel-Ting Hwang, PhD, Dylan G. Scholes, BS,
Tara L. McWilliams, MS: Aditi P. Singh, MD;
Lova Sun, MD, MSCE: John Kosteva, MD;
Michael R. Costello, MD;
Roger B. Cohen, MD; Corey J. Langer, MD;
Abigail Doucette, MPH; Peter N. Gabriel, MD, MSE;
Lawrence N. Shulman, MD, FACP;
Katharine A. Rendle, PhD, MSW, MPH;
Jeffrey C. Thompson, MD: Justin E. Bekelman, MD;
and Erica L. Carpenter, MBA, PhD
INVESTOR 20
DAY 23
Association Between Availability of Molecular Genotyping Results and Overall
Survival in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer²
OS (probability)
1.00
0.75
0.50
0.25
+Available testing group
+ Unavailable testing group
Log-rank
P<.0001
H
0
6
12
18
24
30
36
No. at risk:
Time (months)
Available testing group
Unavailable testing group 65
261
206
154
91
42
14
0
27
14
7
6
2
0
GUARDANT™ 1. Hanna T P, King W D, Thibodeau S, Jalink M, Paulin G A, Harvey-Jones E et al. Mortality due to cancer treatment delay: systematic review and meta-analysis BMJ 2020; 371 :m4087 doi:10.1136/bmj.m4087 2.
Aggarwal, Charu et al. "Association Between Availability of Molecular Genotyping Results and Overall Survival in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer." JCO precision oncology vol. 7
(2023): e2300191. doi:10.1200/PO.23.00191
50
50View entire presentation